Intravenous Hydroxypropyl β‐Cyclodextrin Formulation of Letermovir: A Phase I, Randomized, Single‐Ascending, and Multiple‐Dose Trial

Letermovir is a novel antiviral in clinical development for prophylaxis against human cytomegalovirus in immunocompromised transplant recipients. This two‐part, single‐center, randomized, double‐blind, placebo‐controlled trial evaluated the safety and pharmacokinetics of a hydroxypropyl β‐cyclodextr...

Descripción completa

Detalles Bibliográficos
Autores principales: Erb‐Zohar, K, Kropeit, D, Scheuenpflug, J, Stobernack, H‐P, Hulskotte, EGJ, van Schanke, A, Zimmermann, H, Rübsamen‐Schaeff, H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402190/
https://www.ncbi.nlm.nih.gov/pubmed/28675594
http://dx.doi.org/10.1111/cts.12483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402190/
https://www.ncbi.nlm.nih.gov/pubmed/28675594
http://dx.doi.org/10.1111/cts.12483

Ejemplares similares